Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Ordóñez-Vázquez, Ana Luisa; Beltrán-Gall, Sofía Murúa; Pal, Shreya C; Méndez-Sánchez, Nahum

Ordóñez-Vázquez, Ana Luisa; Beltrán-Gall, Sofía Murúa; Pal, Shreya C; Méndez-Sánchez, Nahum.

Affiliation

Ordóñez-Vázquez AL; Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
Beltrán-Gall SM; Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
Pal SC; Liver Research Unit, Medica Sur Clinic Foundation, Mexico City, Mexico.
Méndez-Sánchez N; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Med Sci Monit ; 28: e938365, 2022 Sep 12.

Article in En | MEDLINE | ID: mdl-36093924

Subject(s)

Diabetes Mellitus, Type 2; Insulin Resistance; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/metabolism; Glucagon-Like Peptide 1/metabolism; Glucose/metabolism; Humans; Incretins/metabolism; Incretins/therapeutic use; United States; Weight Loss

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus, Type 2 Type of study: Risk_factors_studies / Screening_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Med Sci Monit Journal subject: MEDICINA Year: 2022 Type: Article Affiliation country: Mexico

Fulltext

XML

PubMed Links

Search on Google